OR WAIT null SECS
Eudratec Fasteric is an oral drug delivery technology that offers enteric protection after rapid, homogeneous release for targeting the upper small intestine.
Evonik announced on Oct. 6, 2020 that it has launched Eudratec Fasteric, an oral drug delivery technology that offers enteric protection after rapid, homogeneous release for targeting the upper small intestine.
The new technology can release 90% of its dose within 30 minutes of arrival at a pre-defined pH level between 3.0 and 5.5, while increasing gastric resistance and improving intestinal absorption for oral drug products, a company press release said. The technology can be used with standard equipment and a range of oral dosage forms including multiparticulates, tablets, and capsules.
“Many APIs are best absorbed through the proximal part of the small intestine,” said Paul Spencer, head of Pharma Polymers and Services at Evonik, in the press release. “Enteric protection, followed by early, fast, and homogeneous release at the right pH level, can be essential to maximize absorption and enhance bioavailability. With the launch of Eudratec Fasteric, Evonik has addressed another major unmet need for oral drug delivery.”